BioCardia, Inc. Increase (Decrease) in Contract with Customer, Liability
BioCardia, Inc. (BCDA) reported Increase (Decrease) in Contract with Customer, Liability of $691.00 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2019-11-19
- BioCardia, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2018-09-30 was $0.00.
- BioCardia, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2018-06-30 was -$30.00K.
- BioCardia, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2018-03-31 was -$35.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month |
|---|---|---|---|
| 2019-09-30 | $691.00K 10-Q · filed 2019-11-19 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-19 | -$30.00K derived: sum of 2 quarters · filed 2019-11-19 | -$65.00K 10-Q · filed 2019-11-19 |
| 2018-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$65.00K 10-Q · filed 2019-08-14 | |
| 2018-03-31 | -$35.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |